You're in luck if you're looking for a list of biotech stocks to buy. Below is a list of publicly traded companies involved in biotech research and development. Incyte Corporation, Vertex Pharmaceuticals Inc., Anixa Biosciences, and Pitolisant are among these companies.
CRISPR Medicines is a biotech business specializing in developing CRISPR/Cas9-based therapeutics. The company's therapeutic program portfolio aims to prevent and treat type 1 diabetes and hemoglobinopathies. A collaboration with Vertex Pharmaceuticals is also underway to investigate medicines for beta-thalassemia and myotonic dystrophy type 1.
CRISPR Therapeutics had previously reported excellent findings in their sickle cell program, and management recently stated that a novel product candidate for transfusion-dependent beta-thalassemia is in a clinical study. This medication will reduce the amount of hemolysis and anemia that beta-thalassemia patients experience while improving their general health.
Incyte Corporation is a biopharmaceutical multinational corporation. The company, headquartered in Wilmington, DE, manufactures pharmaceuticals in various therapeutic areas. Jakafi, its best-selling product, is approved to treat steroid-refractory acute graft-versus-host disease. Pemigatinib, an investigational cholangiocarcinoma therapy, is also in the works.
Incyte has $813 million in revenue as of the third quarter. Jakafi generates 80% of the company's revenue. The medication has been licensed to treat steroid-refractory acute marrow-versus-host disease, intermediate-risk myelofibrosis, and polycythemia vera. Jakafi reported $466 million in sales in the fourth quarter.
Incyte is working on 21 drugs at various stages of development. Six of these drugs are currently being studied in clinical studies. Several substances are also in late-stage testing.
Anixa Biosciences is a biotechnology business based in San Jose, California. The company's clever small widgets are used in the following industries: vaccinations, cancer, and diagnostics. ITUS Corporation was its last name. The company's name was changed to Anixa Biosciences in October 2018.
Anixa's most remarkable achievement is the development of a revolutionary CAR-T immunotherapy medication. Aside from its latest venture, the organization has a good portfolio of stalwart vaccines and other promising infectious disease medicines. A preventative ovarian cancer vaccine, a new vaccination for triple-negative breast cancer, and many tiny compounds for a wide range of inherited metabolic illnesses are among their more esoteric products.
The company creates antibody-drug conjugates (ADCs) for solid and hematological cancers. They use monoclonal antibodies to target specific tumor antigens and pyrrolobenzodiazepine-based warheads. ADC Therapeutics is developing multiple PBD-based ADCs, including loncastuximab tesirine, camidanlumab tesirine, and ADCT-601.
The primary program of ADC Therapeutics, loncastuximab terrine, is in a phase 2 trial for patients with newly diagnosed diffuse large B-cell lymphoma. In addition to treating patients, the business runs several tests with the medicine and other agents. Its second medicine, camidanlumab tesirine, targets CD25, a cancer cell membrane protein known to promote the growth of various cancers.
Pitolisant is a novel medication used to treat cataplexy in narcoleptic individuals. It has been touted as the first FDA-approved non-scheduled medicine to treat the illness. The drug is currently being tested for broader applications, such as the more prevalent idiopathic hypersomnia, sometimes known as pediatric narcolepsy.
Pitolisant belongs to the H3 blocker drug class. Bioprojet developed the drug, which is already being sold in other nations. The European Medicines Agency approved pitolisant in 2016. (EMA).
Its effects are mild compared to other similar medications; however, it has an outstanding Kd value of 50+-4 pM. Pitolisant, unlike other H3 agonists, has no amphetamine-like effects.
Vertex Pharmaceuticals is a biotechnology firm that creates small-molecule medications to treat acute diseases. Cancer, neurological problems, infectious diseases, and inflammatory bowel disease are all treated with the company's drugs. Its headquarters are located in Boston, Massachusetts. It has offices in the United States, Europe, and Latin America.
Vertex was established in 1989. Its initial focus was on inflammatory disorders and viral infections. It developed protease inhibitors to treat HIV infection in the 1990s.
Vertex had a dozen medicinal candidates in development by 2002. Their mission was to create a robust drug discovery engine. Navia, a rational drug design expert, was hired.
CRISPR Medicines is a biotech business specializing in developing CRISPR/Cas9-based therapeutics. The company's therapeutic program portfolio aims to prevent and treat type 1 diabetes and hemoglobinopathies. A collaboration with Vertex Pharmaceuticals is also underway to investigate medicines for beta-thalassemia and myotonic dystrophy type 1.
CRISPR Therapeutics had previously reported excellent findings in their sickle cell program, and management recently stated that a novel product candidate for transfusion-dependent beta-thalassemia is in a clinical study. This medication will reduce the amount of hemolysis and anemia that beta-thalassemia patients experience while improving their general health.
Incyte Corporation is a biopharmaceutical multinational corporation. The company, headquartered in Wilmington, DE, manufactures pharmaceuticals in various therapeutic areas. Jakafi, its best-selling product, is approved to treat steroid-refractory acute graft-versus-host disease. Pemigatinib, an investigational cholangiocarcinoma therapy, is also in the works.
Incyte has $813 million in revenue as of the third quarter. Jakafi generates 80% of the company's revenue. The medication has been licensed to treat steroid-refractory acute marrow-versus-host disease, intermediate-risk myelofibrosis, and polycythemia vera. Jakafi reported $466 million in sales in the fourth quarter.
Incyte is working on 21 drugs at various stages of development. Six of these drugs are currently being studied in clinical studies. Several substances are also in late-stage testing.
Anixa Biosciences is a biotechnology business based in San Jose, California. The company's clever small widgets are used in the following industries: vaccinations, cancer, and diagnostics. ITUS Corporation was its last name. The company's name was changed to Anixa Biosciences in October 2018.
Anixa's most remarkable achievement is the development of a revolutionary CAR-T immunotherapy medication. Aside from its latest venture, the organization has a good portfolio of stalwart vaccines and other promising infectious disease medicines. A preventative ovarian cancer vaccine, a new vaccination for triple-negative breast cancer, and many tiny compounds for a wide range of inherited metabolic illnesses are among their more esoteric products.
The company creates antibody-drug conjugates (ADCs) for solid and hematological cancers. They use monoclonal antibodies to target specific tumor antigens and pyrrolobenzodiazepine-based warheads. ADC Therapeutics is developing multiple PBD-based ADCs, including loncastuximab tesirine, camidanlumab tesirine, and ADCT-601.
The primary program of ADC Therapeutics, loncastuximab terrine, is in a phase 2 trial for patients with newly diagnosed diffuse large B-cell lymphoma. In addition to treating patients, the business runs several tests with the medicine and other agents. Its second medicine, camidanlumab tesirine, targets CD25, a cancer cell membrane protein known to promote the growth of various cancers.
Pitolisant is a novel medication used to treat cataplexy in narcoleptic individuals. It has been touted as the first FDA-approved non-scheduled medicine to treat the illness. The drug is currently being tested for broader applications, such as the more prevalent idiopathic hypersomnia, sometimes known as pediatric narcolepsy.
Pitolisant belongs to the H3 blocker drug class. Bioprojet developed the drug, which is already being sold in other nations. The European Medicines Agency approved pitolisant in 2016. (EMA).
Its effects are mild compared to other similar medications; however, it has an outstanding Kd value of 50+-4 pM. Pitolisant, unlike other H3 agonists, has no amphetamine-like effects.
Vertex Pharmaceuticals is a biotechnology firm that creates small-molecule medications to treat acute diseases. Cancer, neurological problems, infectious diseases, and inflammatory bowel disease are all treated with the company's drugs. Its headquarters are located in Boston, Massachusetts. It has offices in the United States, Europe, and Latin America.
Vertex was established in 1989. Its initial focus was on inflammatory disorders and viral infections. It developed protease inhibitors to treat HIV infection in the 1990s.
Vertex had a dozen medicinal candidates in development by 2002. Their mission was to create a robust drug discovery engine. Navia, a rational drug design expert, was hired.